|
|
|
市場調査レポート
バイオマーカー：先進技術と世界市場（2009年〜2014年）
Biomarkers- Advanced Technologies and Global Market (2009-2014)
|
Abstract
Report Description
The Global Biomarker Market report analyzes the biomarker tools and services
market over the period 2009-2014. The report studies the major market drivers,
restraints, and opportunities for the global biomarker market; and also
evaluates the major trends in the macro- and micro-markets with respect to
different geographic regions.
The global biomarker market is estimated to be $20.5 billion by 2014, growing
at a CAGR of 19.7 % from 2009 to 2014, driven by the high demand for the
biomarkers in the field of drug discovery. The markets for biomarker tools and
services are expected to grow at a CAGR of 18.5% and 22.2% respectively. The
increasing use of biomarkers in clinical services is boosting the overall
biomarker service market.
The high growth of biomarker market is boosted by the demand from the baby
boomer generation in the U.S., and from Asia' s emerging IT industry. Biomarker
applications are increasing in cancer diagnosis as novel tools are being
developed to increase the discovery speed of cancer biomarkers. The use of
proteomics in biomarker testing and identification has in turn boosted the
services for the biomarkers. Market players are now focusing on new product
and service development to enhance their commercial portfolios. Strategic
collaborations among companies are also increasing biomarker applications in
the field of diagnosis and drug discovery.
SCOPE AND FORMAT
The report analyzes the global biomarker market into the following segments:
- Tools Market (pregenomic biomarkers and technologies, postgenomic
biomarkers and technologies, imaging biomarkers, and others)
- Services Market (pre- and post-clinical biomarker services, sample
preparation, mirna analysis, and others)
- Application Market (diagnosis, and drug development and discovery)
The market data consists of aggregate sales figures of all biomarker
submarkets. It analyzes the market aspects of new biomarker technologies and
product launches; sourcing key market developments from the top companies that
it profiles. The report also analyzes the documented claims and the biomarker
technology patents approved over the last five years to provide an in-depth
understanding of biomarker tools and services.
What makes our report unique?
- Provision of longest market segmentation in the industry.
- The report provides analysis of patents and more than 45 company profiles
giving a competitive outlook.
- The report includes market data for segments such as tools, services and
applications for the major geographies - U.S., Europe, Asian and ROW.
- The high level analysis provided by the report analyzes the market
prospective for different major market segments along with the identification
of opportunities.
- Provided competitive analysis stating the major segments focused by the
global market players and the key developments - tools, services and
technology.
Table of Contents
1. market overview
- 1.1. Defining biomarker
- 1.2. Defining the biomarker market
- 1.3. Biomarker and its applications- Holistic view with respect to
diagnosis and drug discovery
- 1.4. Cardiovascular and cancer diagnosis applications have high priority
in the existing and future market scenario
- 1.5. Biomarker Pre and Post clinical services impacting the biomarker
services market
- 1.6. biomarker patent analysis
2. summary
3. biomarker market dynamics
- 3.1. Drivers
- 3.1.1. high demand for biomarkers in drug discovery
- 3.1.2. BIOMARKERs help in the Early detection of drug failures
- 3.1.3. Biomarkers as cancer diagnostic tools
- 3.1.4. Cro RECOGNIZE VALUE OF biomarkerS IN drug development
- 3.1.5. Development in the life science fields such as proteomics and
genomics enhances the biomarker applications
- 3.1.6. Support from FDA for biomarker development
- 3.2. Restraints
- 3.2.1. regulatory environment restrains the market growth
- 3.2.2. High initial investment hinders biomarker applicability
- 3.2.3. biomarker tests perceived to be unreliable
- 3.2.4. disapproval of diagnotic tools for biomarkers hinders the market
growth
- 3.2.5. Biomarker validation approaches still not clearly addressed
- 3.2.6. Lack of web based solutions for biomarker discovery
- 3.3. Opportunities
- 3.3.1. Translational medicine focus on biomarker
- 3.3.2. accurate and precise measures of diseases
- 3.3.3. Commercial applications in proteomics
4. global biomarker tools market
- 4.1. Drivers:
- 4.1.1. effective software solutions boost biomarker tools
- 4.1.2. Discovery of cancer biomarkers
- 4.2. Pregenomic Biomarkers and Technologies
- 4.2.1. Drivers
- 4.2.1.1. Discovery of new biomarkers stimulates development of
technologies
- 4.2.1.2. Quick diagnosis offered by molecular diagnostics boosts the
growth
- 4.2.2. Molecular Diagnostics
- 4.2.3. Drivers:
- 4.2.3.1. Need for easy to handle and automated techniques drives the
market
- 4.2.3.2. Technological push supports the market growth
- 4.2.4. Immunodiagnostics
- 4.2.5. Drivers:
- 4.2.5.1. Emerging applications of immunoassays supports
immunodiagnostics market
- 4.2.5.2. Need for timely diagnosis and early detection of diseases has
spurred the growth
- 4.2.6. Restraints
- 4.2.6.1. Price erosion hinders the market growth
- 4.2.6.2. Lack of standardization hampers market development
- 4.2.7. Enzyme and Metabolite Assays
- 4.3. Postgenomic Biomarkers and Technologies
- 4.4. Drivers
- 4.4.1. High demand for medical requirements boosts technological growth
- 4.4.2. greater stress on individual risk assessment
- 4.5. Restraints
- 4.5.1. High cost of genomics platform
- 4.5.2. FDA approval poses a big challenge for market participants
- 4.6. Opportunities
- 4.6.1. Emerging field of nutrition research to support the market growth
- 4.6.2. Proteomics
- 4.6.3. Drivers
- 4.6.3.1. Need to enhance the efficiency and speed of drug discovery
process
- 4.6.3.2. Potential of proteomics in personalized therapy development
- 4.6.4. Restraints
- 4.6.4.1. Expensive proteomics analysis tools leads to low adoption rates
- 4.6.4.2. Technological need for speeding up validation process
- 4.6.5. Mass Spectrometry in Biomarker Discovery and Validation
- 4.6.6. Drivers
- 4.6.6.1. Easy quantification of the protein structures created the need
for mass spectrometry
- 4.6.6.2. Rising popularity of integrated MS tools boosts the growth
- 4.6.7. Metabolomics
- 4.6.8. Drivers
- 4.6.8.1. Emergence of Proteomics-sciences in the field of drug
development spurs the market size.
- 4.6.8.2. Rapid growth of metabolomics data analysis software and solution
- 4.6.9. 2D Gel Electrophoresis
- 4.6.10. Differential In-gel Electrophoresis
- 4.6.11. Transcriptomics
- 4.6.11.1. Positional DNA Microarrays
- 4.6.11.2. Encoded Particle Arrays
- 4.6.12. Analysis of Metabolites in Biological Specimens
- 4.6.12.1. Disease-Related Biomarkers
- 4.6.12.2. Metabolite Profiling for Biomarker Discovery
- 4.6.13. Imaging Biomarkers
- 4.6.14. Drivers
- 4.6.14.1. Rising applications of imaging biomarkers in the drug
development
- 4.6.14.2. Success of imaging biomarkers in several diseases
- 4.6.14.3. Molecular Imaging
- 4.6.14.4. Magnetic Resonance Imaging
- 4.6.14.5. Positron Emission Tomography
- 4.6.14.6. FDG-PET Patient Phase I Studies
- 4.6.14.7. Imaging Biomarkers as Study Endpoints
- 4.6.15. Others
- 4.6.15.1. Bioinformatics
- 4.6.15.2. Reagents
5. global biomarker services market
- 5.1. Drivers
- 5.1.1. emergence of contract research organizations as service providers
- 5.1.2. High ROI from investment in biomarker discovery by the
PHARMACEUTICAL INDUSTRY
- 5.2. Biomarker Pre and Post Clinical Services
- 5.3. Drivers
- 5.3.1. Biomarkers boost the efficiency in the drug discovery process.
- 5.3.2. High duration and cost of the clinical trials drives the services
- 5.3.3. Biomarker Testing
- 5.3.4. Assay Development
- 5.4. Antibody Development
- 5.4.1. Validation and Reporting
- 5.5. Sample Preparation
- 5.5.1. Blood/biofluids
- 5.5.2. Cell lines - eukaryotic and prokaryotic
- 5.5.3. Frozen/RNAlater/RNAretain tissues
- 5.6. Other services
- 5.6.1. Bioinformatics Services
- 5.6.2. Data Analysis
- 5.6.3. mRNA Analysis
- 5.7. miRNA Analysis
- 5.7.1. miRNA Microarray Service
- 5.7.2. miRNA Expression Profiling
6. global biomarker applications market
- 6.1. Drivers:
- 6.1.1. Demand for early predictive technologies into pre-clinical and
early clinical development phase
- 6.1.2. Developments in high-throughput technologies, systems biology and
bioinformatics
- 6.1.3. Development of safer drugs with increased therapeutic efficacy in
a cost-effective manner
- 6.1.4. Less expense of genetic biomarkers incorporated for genotyping
boosting the demand for the same.
- 6.2. Restraints:
- 6.2.1. Biomarker without clinical validation generates erroneous end
points
- 6.2.2. Large varieties of biomarkers delay evaluation, clinically
- 6.2.3. Uncertainties in Pharmacogenomics Testing Hinders Market Adoption
- 6.2.4. Ethical Issues regarding Patient' s Confidentiality and Rights
Pose another Area of concern.
- 6.3. Diagnosis
- 6.4. Market Drivers:
- 6.4.1. Adoption of biomarker for cancer diagnosis
- 6.4.2. Current development and research driving the biomarker market for
cancer diagnosis.
- 6.4.2.1. Ovarian Cancer Diagnostics
- 6.4.2.2. HER2 Breast cancer Diagnostics
- 6.4.2.3. Bladder Cancer
- 6.4.2.4. Cervical Cancer Diagnostics
- 6.4.2.5. Prostate Cancer
- 6.4.3. Cardiovascular and Metabolic Diseases:
- 6.5. Market Drivers:
- 6.5.1. Cardiovascular Biomarkers potential to accurately detect heart
failure.
- 6.5.2. Biomarkers facilitate enhanced diagnosing and managing metabolic
disease
- 6.6. Restraints
- 6.6.1. Specific technical requirements are unmet
- 6.6.2. Autoimmune disease and inflammatory diseases
- 6.7. Drivers
- 6.7.1. Need for effective treatment and diagnosis
- 6.8. Restraints
- 6.8.1. Lack of understanding of the disease cause among researchers and
scientists.
- 6.8.2. Neurological Diseases:
- 6.9. Drivers
- 6.9.1. Patients demand for rapid diagnosis and treatment
- 6.9.2. Precaution and effective clinical diagnosis for autoimmune
diseases
- 6.10. Restraints
- 6.10.1. Limitations in the reimbursement systems
- 6.10.2. The costs for diagnostics are starting to be offset against the
savings in other areas
- 6.10.2.1. Alzheimer' s disease
- 6.10.2.1.1. Image based biomarkers
- 6.10.2.1.2. Genetic Markers
- 6.10.2.1.3. Biomarkers in blood:
- 6.10.2.1.4. Biomarkers in cerebrospinal fluid
- 6.10.2.2. Schizophrenia:
- 6.10.2.3. Parkinson' s disease:
- 6.10.3. Tuberculosis:
- 6.11. Market DRiver
- 6.11.1. Biomarkers ability to accelerate and streamline drug development
for tuberculosis.
- 6.11.2. Rise in the drug resistant tuberculosis
- 6.11.2.1. Stroke Diagnosis
- 6.12. Driver
- 6.12.1. Rising incidence of stroke globally has boosted the need for
biomarkers
- 6.12.2. Transition in dietary intake globally
- 6.13. Drug Development & Discovery
- 6.13.1. Drug Targets
- 6.13.1.1. Target Validation
- 6.13.1.1.1. Target Discovery
- 6.13.1.2. Target Discovery Using Functional Genomics
- 6.13.2. ADME-TOX profiling
- 6.13.3. Drug development and process quality assurance
7. ographical analysis of biomarker market
- 7.1. north america:
- 7.2. Europe:
- 7.3. Asia:
- 7.4. row:
8. competitive landscape
9. company profiles
- 9.1. Affymetrix
- 9.2. Agilent Technologies
- 9.3. Amgen
- 9.4. Ariadne
- 9.5. Banyan Biomarkers Inc.
- 9.6. BG Medicine
- 9.7. Biophysical Corp
- 9.8. BioSystems International (BSI)
- 9.9. Calibrant
- 9.10. Caprion Proteomics
- 9.11. Correlogic Systems Inc
- 9.12. Cyclacel
- 9.13. deCODE
- 9.14. Epigenomics
- 9.15. Exagen Diagnostics Inc.
- 9.16. GE Healthcare
- 9.17. Genedata
- 9.18. GeneGo
- 9.19. GeneNews
- 9.20. Gyros AB
- 9.21. Human Metabolome Technologies (HMT)
- 9.22. Illumina Inc
- 9.23. Imgenex
- 9.24. InforSense
- 9.25. Ingenuity Systems
- 9.26. Insilicos
- 9.27. Integromics
- 9.28. MDS Inc
- 9.29. Metabolon Inc
- 9.30. Metanomics Health GmBH
- 9.31. MicroDiscovery
- 9.32. Molecular Connections
- 9.33. Nanogen
- 9.34. NextGen Group PLC
- 9.35. Nonlinear USA Inc
- 9.36. Nuvera Biosciences
- 9.37. Ocimum Biosolutions
- 9.38. Pam Gene BV
- 9.39. Partek
- 9.40. Pronota
- 9.41. Perlegen
- 9.42. Phenomenome Discoveries Inc
- 9.43. Siemens Healthcare
- 9.44. Singulex
- 9.45. Softgenetics llc
- 9.46. Tyrian
- 9.47. Zeptosens
- 9.48. Patents for united states
- 9.49. Patents for europe
- 9.50. Patents for japan
LIST OF TABLES
- SUMMARY TABLE Global biomarker market BY tools and services 2009 - 2014
($ thousands)
- Table 1 Global Bio marker Tools market by Product 2007-2014 ($ thousands)
- Table 2 Global Bio marker Tools market by Geography 2007-2014 ($
thousands)
- Table 3 Global Pregenomic Biomarkers and Technologies market by Product
2007-2014 ($ thousands)
- Table 4 Global Pregenomic Biomarkers and Technologies market by Geography
2007-2014 ($ thousands)
- Table 5 Global Molecular Diagnostics market by Product 2007-2014 ($
thousands)
- Table 6 Global Molecular Diagnostics market byGeography 2007-2014 ($
thousands)
- Table 7 Global Immunodiagnostics market by Geography 2007-2014 ($
thousands)
- Table 8 Global Enzyme and Metabolite Assays market byGeography 2007-2014
($ thousands)
- Table 9 Global Post genomic Bio markers and Technologies market by
Product 2007-2014 ($ thousands)
- Table 10 Global Post genomic Bio markers and Technologies market by
Geography 2007-2014 ($ thousands)
- Table 11 Global Proteomics market by Product 2007-2014 ($ thousands)
- Table 12 Global Proteomics market by Geography 2007-2014 ($ thousands)
- Table 13 Global Mass Spectrometry in Bio marker Discovery and Validation
market by Geography 2007-2014 ($ thousands)
- Table 14 Global Metabolomics market by Geography 2007-2014 ($ thousands)
- Table 15 Global 2D Gel Electrophoresis market by Geography 2007-2014 ($
thousands)
- Table 16 Global Differential In-gel Electrophoresis market by Geography
2007-2014 ($ thousands)
- Table 17 Global Transcriptomics market by Product 2007-2014 ($ thousands)
- Table 18 Global Transcriptomics market by Geography 2007-2014 ($
thousands)
- Table 19 Global Positional DNA Microarrays market by Geography 2007-2014
($ thousands)
- Table 20 Global Encoded Particle Arrays market by Geography 2007-2014 ($
thousands)
- Table 21 Global Analysis of Metabolites in Biological Specimens market by
Product 2007-2014 ($ thousands)
- Table 22 Global Analysis of Metabolites in Biological Specimens market by
Geography 2007-2014 ($ thousands)
- Table 23 Global Disease-Related Biomarkers market byGeography 2007-2014
($ thousands)
- Table 24 Global Metabolite Profiling for Bio marker Discovery market by
Geography 2007-2014 ($ thousands)
- Table 25 Global Imaging Biomarkers market by Product 2007-2014 ($
thousands)
- Table 26 Global Imaging Biomarkers market by Geography 2007-2014 ($
thousands)
- Table 27 Global Molecular Imaging market by Geography 2007-2014 ($
thousands)
- Table 28 Global Magnetic Resonance Imaging market by Geography 2007-2014
($ thousands)
- Table 29 Global Positron Emission Tomography market by Geography
2007-2014 ($ thousands)
- Table 30 Global FDG-PET Patient Phase I Studies market by Geography
2007-2014 ($ thousands)
- Table 31 Global Imaging Bio markers as Study Endpoints market by
Geography 2007-2014 ($ thousands)
- Table 32 Global Others market by Product 2007-2014 ($ thousands)
- Table 33 Global Others market by Geography 2007-2014 ($ thousands)
- Table 34 Global Bioinformatics market by Geography 20072014 ($ thousands)
- Table 35 Global Reagents market by Geography 2007-2014 ($ thousands)
- Table 36 Global Biomarker Services market by Product 2007-2014 ($
thousands)
- Table 37 Global Bio marker Services market by Geography 2007-2014 ($
thousands)
- Table 38 Global Biomarker Pre and Post Clinical Services market by
product 2007-2014 ($ thousands)
- Table 39 Global Biomarker Pre and Post Clinical Services market by
Geography 2007-2014 ($ thousands)
- Table 40 Global Biomarker Testing market by Geography 2007-2014 ($
thousands)
- Table 41 Global Assay Development market by Geography 2007-2014 ($
thousands)
- Table 42 Global Antibody Development market by Geography 2007-2014 ($
thousands)
- Table 43 Global Validation and Reporting market by Geography 2007-2014 ($
thousands)
- Table 44 Global Sample Preparation market by Product 2007-2014 ($
thousands)
- Table 45 Global Sample Preparation market by Geography 2007-2014 ($
thousands)
- Table 46 Global Blood/bio fluids market by Geography 200 - 2014 ($
thousands)
- Table 47 Global Cell lines - eukaryotic and prokaryotic market by
Geography 200 - 2014 ($ thousands)
- Table 48 Global Frozen/RNAlater/RNAretain tissues marketby Geography
2007-2014 ($ thousands)
- Table 49 Global other services market by product 2007-2014 ($ thousands)
- Table 50 Global other services market by geography 2007-2014 ($ thousands)
- Table 51 Global bioinformatics services market BY GEOGRAPHY 2007-2014 ($
thousands)
- Table 52 Global data analysis market by geography 2007-2014 ($ thousands)
- Table 53 Global mrna analysis market by geography 2007-2014($ thousands)
- Table 54 Global mirna analysis market by product 2007-2014 ($ thousands)
- Table 55 Global mirna analysis market by geography 2007-2014 ($ thousands)
- Table 56 Global mirna microarray service market by geography 2007-2014 ($
thousands)
- Table 57 Global miRNA expresion profiling market by geography 2007-2014
($ thousands)
- Table 58 Global biomarker applications market 2007-2014 ($ thousands)
- Table 59 Global diagnosis market by product 2007-2014 ($ thousands)
- Table 60 Global cancer diagnosis market by product 2007-2014 ($
thousands)
- Table 61 Global neurological disease market by product 2007-2014 ($
thousands)
- Table 62 Global alzheimer' s disease market by product 2007-2014 ($
thousands)
- Table 63 Global drug development and discovery market by product
2007-2014 ($ thousands)
- Table 64 Global drug target market by product 2007-2014 ($ thousands)
- Table 65 Global target validation market by product 2007-2014 ($
thousands)
- TABLE 66 NORTH AMERICAn BIOmarker MARKET 2007-2014 ($ thousands)
- TABLE 67 european BIOmarker MARKET 2007-2014 ($ thousands)
- TABLE 68 asian BIOmarker MARKET 2007-2014 ($ thousands)
- TABLE 69 row BIOmarker MARKET 2007-2014 ($ thousands)
- table 70 NEW PRODUCT, TECHNOLOGY, SERVICE LAUNCH (2008-2009)
- table 71 list of agreements and collaborations (2008-2009)
LIST OF FIGURES
- Figure 1 biomarker discovery
- figure 2 evolution of biomarkers and future shift Defining the biomarker
market
- Figure 3 Biomarker market segmentation
- figure 4 Business architecture
- figure 5 biomarker opportunity
- figure 6 biomarker challenges
- figure 7 biomarker applications market prospective
- Figure 8 Biomarker applications market dynamics
- Figure 9 Biomarker services markeT dynamics
- figure 10 patent analysis by technology 2006 to 2008
- figure 11 Patent analysis by competitors (2004-2008)
- figure 12 patent analysis by geography
- Figure 13 Biomarker clinical trial effectiveness
- Figure 14 Biomarker applications in molecular diagnostics
- Figure 15 imaging biomarkers APPLICATIONS in drug development
- Figure 16 Common bioinformatics microarrays for biomarker discovery
- Figure 17 Biomarker areas in drug development process
- Figure 18 Global biomarker market by geography
- Figure 19 Global biomarker tools market by geography
- Figure 20 Global biomarker service market by geography
- figure 21 geography wise biomarker market- global perspective
- figure 22 Major segments focused by global biomarker players
- Figure 23 Competitive landscape for strategy formation (2008-2009)
|
 |
